Head to Head Analysis: Eloxx Pharmaceuticals (NASDAQ:ELOX) and Journey Medical (NASDAQ:DERM)

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Journey Medical shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of -1864.08, suggesting that its share price is 186,508% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Eloxx Pharmaceuticals and Journey Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	1	2.75
Journey Medical	1	1	2	0	2.25

Eloxx Pharmaceuticals presently has a consensus price target of $41.50, indicating a potential upside of 97.81%. Journey Medical has a consensus price target of $14.00, indicating a potential upside of 80.65%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than Journey Medical.

Profitability

This table compares Eloxx Pharmaceuticals and Journey Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Journey Medical	-8.95%	-20.23%	-6.60%

Valuation and Earnings

This table compares Eloxx Pharmaceuticals and Journey Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	13.33	-$5.99 million	($1.54)	-13.62
Journey Medical	$61.86 million	3.45	-$11.43 million	($0.22)	-35.23

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eloxx Pharmaceuticals beats Journey Medical on 10 of the 14 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.